A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Phase 2 Completed 27 enrolled Dana-Farber Cancer Institute

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.

Timeline

Start: 2016-10-12
Primary completion: 2020-09-30
Completion: 2021-07-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prexasertib	Small molecule	105 mg/m2	Intravenous

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Summary

Timeline

Drugs

Indications